Nuvectis Pharma Q1 net loss $2.9M; cash $16.7M; NXP800 Phase 1 dose escalation ongoing

Nuvectis Pharma, Inc.

2022-Q1 EPS reported $0.32

Net loss of $2.9M for Q1 2022, including $0.2M non-cash expense.
Cash, cash equivalents and short-term investments of $16.7M at March 31, 2022, up from $5.7M at Dec 31, 2021 due to IPO.
R&D expenses $1.8M; G&A expenses $1.1M for the quarter.
NXP800 Phase 1 dose escalation portion ongoing; presented at 2022 AACR 'New Drugs on the Horizon'.
Completed IPO in Feb 2022 raising $16M gross proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.